
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **COL17A1**: Known for its role in cell adhesion and maintaining the integrity of epithelial cells.<br>- **TAGLN (Transgelin)**: Associated with smooth muscle cells and involved in actin binding.<br>- **MYH11 (Myosin Heavy Chain 11)**: A marker for smooth muscle cells, involved in muscle contraction.<br>- **ACTA2 (Alpha-Smooth Muscle Actin)**: A classic marker for smooth muscle cells, involved in muscle contraction.<br>- **MYLK (Myosin Light Chain Kinase)**: Involved in muscle contraction and regulation of actin-myosin interactions.<br>- **CALD1 (Caldesmon 1)**: Involved in smooth muscle contraction.<br>- **TPM2 (Tropomyosin 2)**: Involved in muscle contraction.<br>- **ACTG2 (Actin Gamma 2)**: Associated with smooth muscle contraction.<br>- **ANO1 (Anoctamin 1)**: Involved in calcium-activated chloride channel activity, often found in smooth muscle cells.<br><br>### Step 2: List the Key Cell Type Markers<br>- **KRT17 (Keratin 17)**: Typically expressed in epithelial cells, particularly in basal cells of stratified epithelia.<br>- **KRT14 (Keratin 14)**: A marker for basal epithelial cells, often found in the basal layer of the epidermis.<br>- **KRT5 (Keratin 5)**: Another marker for basal epithelial cells, often co-expressed with KRT14.<br>- **S100A2**: Often expressed in epithelial cells and associated with cell differentiation.<br>- **LAMB3 (Laminin Subunit Beta 3)**: Part of the basement membrane, associated with epithelial cells.<br>- **DST (Dystonin)**: Involved in cytoskeletal organization, often found in epithelial cells.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and PanglaoDB, we can cross-reference these markers:<br>- **Smooth Muscle Markers**: MYH11, ACTA2, TAGLN, MYLK, CALD1, TPM2, ACTG2, ANO1 are strongly indicative of smooth muscle cells.<br>- **Basal Epithelial Markers**: KRT17, KRT14, KRT5, LAMB3, DST suggest a basal epithelial cell type, often found in the basal layer of stratified epithelia.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of these markers, the most probable general cell type is **myoepithelial cells**. Myoepithelial cells are known to express both smooth muscle markers (such as ACTA2, MYH11) and basal epithelial markers (such as KRT14, KRT5).<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Myoepithelial Cells**: Given the strong expression of both smooth muscle and basal epithelial markers, myoepithelial cells are the most likely subtype.<br>2. **Basal Epithelial Cells**: The presence of KRT14, KRT5, and KRT17 suggests basal epithelial cells as a possible subtype.<br>3. **Smooth Muscle Cells**: The expression of smooth muscle markers like MYH11 and ACTA2 could also indicate smooth muscle cells, although the presence of epithelial markers makes this less likely.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of myoepithelial cells. This conclusion is supported by the co-expression of smooth muscle markers (e.g., ACTA2, MYH11) and basal epithelial markers (e.g., KRT14, KRT5). Myoepithelial cells are known to play a role in the contractile function of glandular tissues and are commonly found in breast tissue.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation of the cell cluster as myoepithelial cells is consistent with the provided marker list and the analysis steps outlined. Here's the breakdown:<br><br>1. **Marker Consistency**:<br>   - The markers used in the annotation (e.g., MYH11, ACTA2, TAGLN, KRT14, KRT5) are present in the provided marker list.<br>   - The identified cell type, myoepithelial cells, is consistent with the expression of both smooth muscle markers (e.g., MYH11, ACTA2) and basal epithelial markers (e.g., KRT14, KRT5).<br><br>2. **Mixed Cell Type Consideration**:<br>   - The analysis acknowledges the potential presence of basal epithelial cells and smooth muscle cells as subtypes, which is appropriate given the expression of their respective markers.<br>   - The conclusion that myoepithelial cells are the most likely cell type is well-supported by the co-expression of markers from both smooth muscle and basal epithelial categories.<br><br>Overall, the annotation is well-supported by the marker data and the analysis steps, and no significant issues were identified that would warrant a revision.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">myoepithelial cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>basal epithelial cells</li><li>smooth muscle cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided for the single-cell dataset derived from human breast cancer tissue are generally well-executed, with a few areas that could be improved. Here is a detailed evaluation:<br><br>1. **Correctness of the Annotations**: The final annotation identifies the main cell type as myoepithelial cells, which is a reasonable conclusion given the co-expression of both smooth muscle markers (e.g., MYH11, ACTA2) and basal epithelial markers (e.g., KRT14, KRT5). This is consistent with the known biology of myoepithelial cells, which exhibit characteristics of both cell types. The annotation also considers basal epithelial cells and smooth muscle cells as potential subtypes, which is appropriate given the marker expression.<br><br>2. **Balanced Consideration of Multiple Markers**: The analysis does a good job of considering a range of markers rather than over-focusing on a specific one. The markers are categorized into functional and cell type markers, and the analysis cross-references known databases to support the conclusions. This approach ensures a balanced consideration of the data.<br><br>3. **Ability to Capture the General Picture**: The annotation captures the general picture of the cell populations present in the dataset. By identifying myoepithelial cells as the main cell type and acknowledging the presence of basal epithelial and smooth muscle cells, the analysis provides a comprehensive view of the cell types present.<br><br>4. **Consideration of Marker Rank**: While the analysis does not explicitly mention the rank of the markers, it does focus on key markers that are known to be significant for identifying the cell types in question. However, a more explicit consideration of the rank of the markers could strengthen the analysis.<br><br>5. **Potential Oversights**: There are no obvious misclassifications in the annotation. However, the analysis could benefit from a more detailed discussion of the potential presence of other cell types that might be indicated by less prominent markers in the list.<br><br>Overall, the annotation is scientifically accurate and provides a comprehensive view of the cell types present in the dataset. The analysis is well-supported by the marker data and the steps taken to reach the final conclusion.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    